Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.66 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.65 |
| ▸ | OSBP | P22059 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | RORC | P51449 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.60 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | UGCG | Q16739 | 2/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565939 | 1.00 | POLA1 (0.66) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL8097147 | 1.00 | POLA1 (0.66) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL25352991 | 1.00 | POLA1 (0.66) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL27084012 | 0.92 | POLA1 (0.59) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL12290965 | 0.92 | POLA1 (0.69) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL767548 | 0.92 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL246636 | 0.92 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL246635 | 0.92 | POLA1 (0.73) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL12349231 | 0.92 | POLA1 (0.67) | POLA1CYP46A1OSBPUSP2RORC | |
| SCHEMBL25353279 | 0.90 | POLB (0.63) | POLA1CYP46A1OSBPRORCOSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4704816-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ModernaTX, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024229321-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023076605-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220306573-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-09-29 | — | — | US | disclosed |
| US-9820942-B2 | Lipidosome preparation, preparation method and application thereof | BIOMICS BIOTECHNOLOGIES CO., LTD. (CN) | 2017-11-21 | — | — | US | disclosed |
| US-20150272886-A1 | LIPIDOSOME PREPARATION, PREPARATION METHOD AND APPLICATION THEREOF | BIOMICS BIOTECHNOLOGIES CO., LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-6046306-A | SOLID PHASE SYNTHESIS OF PEPTIDE NUCLEIC ACIDS ALLOWING OLIGOMER TO BE CLEAVED OFF FROM THE SOLID SUPPORT UNDER THE ALKALINE CONDITIONS CONVENTIONALLY USED FOR OLIGONUCLEOTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | POLA1 184/4885CYP46A1 4726/4885OSBP 1104/4885 |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | POLA1 1481/4885CYP46A1 1475/4885OSBP 1024/4885 |
| US-20220306573-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RBM17, UPF1, RBM22 | POLA1 508/4885CYP46A1 4794/4885OSBP 3385/4885 |
| US-20150272886-A1 | LIPIDOSOME PREPARATION, PREPARATION METHOD AND APPLICATION THEREOF | PHOSPHO1, PLTP, LIPA | POLA1 1197/4885CYP46A1 227/4885OSBP 1395/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | POLA1 2294/4885CYP46A1 156/4885OSBP 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.